PROFOUND MEDICAL CORP. Share-based Compensation Arrangements by Share-based Payment Award, Options, Grants in Period, Weighted Average Exercise Price
PROFOUND MEDICAL CORP. (PROF) reported Share-based Compensation Arrangements by Share-based Payment Award, Options, Grants in Period, Weighted Average Exercise Price of 8.29 CAD/shares for the 6-month period ending 2026-06-30, per its 10-Q filed 2026-08-06.
Financial Statements › Notes › Share-Based Payment Arrangement, Disclosure
us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice · last filed 2026-08-06
- PROFOUND MEDICAL CORP. share-based compensation arrangements by share-based payment award, options, grants in period, weighted average exercise price for the quarter ending 2026-03-31 was 7.58 CAD/shares, a 23.20% decline year-over-year.
- PROFOUND MEDICAL CORP. share-based compensation arrangements by share-based payment award, options, grants in period, weighted average exercise price for the quarter ending 2025-03-31 was 9.87 CAD/shares.
- PROFOUND MEDICAL CORP. share-based compensation arrangements by share-based payment award, options, grants in period, weighted average exercise price for fiscal 2025 was 6.70 CAD/shares, a 39.86% decline from fiscal 2024.
- PROFOUND MEDICAL CORP. share-based compensation arrangements by share-based payment award, options, grants in period, weighted average exercise price for fiscal 2024 was 11.14 CAD/shares, a 27.76% decline from fiscal 2023.
- PROFOUND MEDICAL CORP. share-based compensation arrangements by share-based payment award, options, grants in period, weighted average exercise price for fiscal 2023 was 15.42 CAD/shares.
| Period end | Share-based Compensation Arrangements by Share-based Payment Award, Options, Grants in Period, Weighted Average Exercise Price 3 month | Share-based Compensation Arrangements by Share-based Payment Award, Options, Grants in Period, Weighted Average Exercise Price 6 month | Share-based Compensation Arrangements by Share-based Payment Award, Options, Grants in Period, Weighted Average Exercise Price 9 month | Share-based Compensation Arrangements by Share-based Payment Award, Options, Grants in Period, Weighted Average Exercise Price 12 month |
|---|---|---|---|---|
| 2026-06-30 | 8.29 CAD/shares 10-Q · filed 2026-08-06 | |||
| 2026-03-31 | 7.58 CAD/shares 10-Q · filed 2026-05-07 | |||
| 2025-12-31 | 6.70 CAD/shares 10-K · filed 2026-03-05 | |||
| 2025-09-30 | 6.70 CAD/shares 10-Q · filed 2025-11-13 | |||
| 2025-06-30 | 6.87 CAD/shares 10-Q · filed 2025-08-14 | |||
| 2025-03-31 | 9.87 CAD/shares 10-Q · filed 2025-05-08 | |||
| 2024-12-31 | 11.14 CAD/shares 10-K · filed 2026-03-05 | |||
| 2023-12-31 | 15.42 CAD/shares 10-K · filed 2025-03-07 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Neuronetics, Inc. (STIM) | United States | $0.216B | -3.25 |
| PRO DEX INC (PDEX) | United States | $0.234B | 13.64 |
| UTAH MEDICAL PRODUCTS INC (UTMD) | United States | $0.238B | 20.93 |
| Lucid Diagnostics Inc. (LUCD) | United States | $0.170B | |
| InfuSystem Holdings, Inc (INFU) | United States | $0.253B | 22.52 |
| KORU Medical Systems, Inc. (KRMD) | United States | $0.151B | -106.78 |
| Anika Therapeutics, Inc. (ANIK) | United States | $0.272B | -51.71 |
| ORASURE TECHNOLOGIES INC (OSUR) | United States | $0.272B | -6.26 |
| Cytosorbents Corp (CTSO) | United States | $0.274B | -1.29 |
| TriSalus Life Sciences, Inc. (TLSI) | United States | $0.283B | -9.92 |